Lynne Wagenknecht to Lipoproteins, HDL
This is a "connection" page, showing publications Lynne Wagenknecht has written about Lipoproteins, HDL.
Connection Strength
0.140
-
Freedman BI, Langefeld CD, Lu L, Palmer ND, Smith SC, Bagwell BM, Hicks PJ, Xu J, Wagenknecht LE, Raffield LM, Register TC, Carr JJ, Bowden DW, Divers J. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 2015 Jan; 87(1):176-81.
Score: 0.102
-
Hellwege JN, Palmer ND, Raffield LM, Ng MC, Hawkins GA, Long J, Lorenzo C, Norris JM, Ida Chen YD, Speliotes EK, Rotter JI, Langefeld CD, Wagenknecht LE, Bowden DW. Genome-wide family-based linkage analysis of exome chip variants and cardiometabolic risk. Genet Epidemiol. 2014 May; 38(4):345-52.
Score: 0.025
-
Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation. 2005 Jun 28; 111(25):3465-72.
Score: 0.014